- Home
- Experience of drug treatment benign prostatic glands with sexual disorders
Experience of drug treatment benign prostatic glands with sexual disorders
HEALTH OF WOMAN. 2016.10(116):69–75; doi 10.15574/HW.2016.116.69 Experience of drug treatment benign prostatic glands with sexual disorders
National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev
1. Kolesnik NA, Nepomnyaschiy VN, Samuseva ES. 2006. Teoriya i praktika dokazatelnoy meditsinyi. K, Poligrafplyus:200. 2. Pasechnikov SP. 2015. Printsipi klasifikatsiyi. Diagnostika ta likuvannya dobroyakisnoyi giperplaziyi peredmihurovoyi zalozi. Med. aspekty zdorovya muzhchiny 4(19):5–10. 3. Traysh AM, Kim NN, Goldsteyn I. 2008. Testosteron i erektilnaya disfunktsiya: ot fundamentalnih issledovaniy k novoy klinicheskoy paradigme lecheniya muzhchin s vozrastnyim androgennyim defitsitom i erektilnoy disfunktsiey. Zdorove muzhchiny 1:24–36 4. European Association of Urology. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. 2015: 21. 5. Giuliano F et al. 2013. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur. Urol. 63:506–616. https://doi.org/10.1016/j.eururo.2012.09.006; PMid:23018163 6. Rosen RC, Altwein J, Boyl P et al. 2003. Lower urinary tract symptoms and male sexual dysfunction: the Multi-National surgery of the ageing male (MSAM-7). Eur. Urol. 44:637–649. https://doi.org/10.1016/j.eururo.2003.08.015; PMid:14644114 7. Seki N, Naito S, Oshima S. 2003. Prevalence and preference with regard to various surgical treatment for benign prostatic hypertrophy: a survey for the Japanese endourology and ESWL society member. Nippon Hinyokika Gakkai Zasshi 94; 4: 495–502. https://doi.org/10.5980/jpnjurol1989.94.495 8. Donatucci CF, Brock GB, Goldfischer ER et al. 2011. Tabalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 107(7):1110–6. https://doi.org/10.1111/j.1464-410X.2010.09687.x; PMid:21244606 9. Green R, Hicks RW. 2011. Orally disintegrating vardenafil tablets for the treatment of erectile dysfunction: efficacy, safety, and patient acceptability. Patient Prefer Adherence. 5:181–185. https://doi.org/10.2147/PPA.S14030; PMid:21573049 PMCid:PMC3090379 10. Nishikawa G, Ikawab K, Nakamura K et al. 2013. Prostatic penetration of meropenem гhumans, and dosage considerations hiprostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation. Int. J. Antimicrobial Agents. 41:267–271. https://doi.org/10.1016/j.ijantimicag.2012.11.001; PMid:23313536 11. Shabsigh R. 2004. Testosterone therapy in erectile dysfunction. Aging Male. 7:312–318. https://doi.org/10.1080/13685530400016540; PMid:15799127
|